This week, we have conversations with Marc Hedrick, CEO of Cerenome, about a combined approach to tackling central nervous system (CNS) cancers, and Shaun Holt, CEO of Alveo Technologies, about the potential for animal diseases to jump to humans, and what we can do about it.

Times:

03:27 Cerenome

28:27 Alveo Technologies

Cerenome

Cerenome, formerly known as Plus Therapeutics, is a central nervous system (CNS) oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers.

The company’s CNSide Diagnostics platform supports the detection, molecular characterisation, and longitudin ...